Press Releases

- Without an NOC, Ruzurgi ® is without a Marketing Authorization in Canada - Matter Remanded Back to Health Canada to Provide a More Transparent Record of Its Decision in Light of Firdapse ® ’s Data Protection CORAL GABLES, Fla. , June 03, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc.

CORAL GABLES, Fla. , May 19, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases,

-Firdapse® Q1 2021 Net Revenues of $30.2 Million -First Quarter 2021 GAAP Net Income of $7.7 Million ; Non-GAAP Net Income of $11.6 Million -Recently Received Orphan Drug Designation for Firdapse® in Japan - $143.3 Million in Cash and Investments and no Funded Debt at end of Q1-2021 -Catalyst to

CORAL GABLES, Fla. , May 03, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases,

CORAL GABLES, Fla. , March 22, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological

- Firdapse ® Q4-20 Net Revenues of $31.0 Million , FY-20 Net Revenues of $119.1 Million - GAAP Net Income of $75.0 Million for Fiscal Year 2020 - $140.3 Million in Cash and Investments and No Funded Debt - Company to Host Quarterly Conference Call at 8:30 am ET Tomorrow CORAL GABLES, Fla.

CORAL GABLES, Fla. , March 04, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological

Catalyst Supporting Facebook Live Panel on Living with a Rare Disease Hosted by The Mighty Catalyst Kicks off Rare Reason Campaign CORAL GABLES, Fla. , Feb. 22, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on

Company to Expand R&D Focus for Pipeline Growth to include Earlier Stage Programs and Validated Technology Platforms Firdapse® 2020 Net Revenues Estimate of approximately $118 Million ; about 16% Increase From 2019 Ended 2020 with Estimated $140 Million in Cash and Investments Company Highlights